<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for small-cell lung cancer: Single-agent topotecan&lt;SUP&gt;[1]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for small-cell lung cancer: Single-agent topotecan<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for small-cell lung cancer: Single-agent topotecan<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 21 days.<br/> <strong>Duration of therapy:</strong> Until disease progression or for 2 cycles beyond best response. 4 cycles minimum is recommended for stable disease. </td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Topotecan</td> <td style="border-bottom-color: white;">2.3 mg/m<sup>2</sup> per day by mouth*<sup>¶</sup></td> <td style="border-bottom-color: white;">By mouth: Administer once daily without regard to meals. Do not open or crush capsule.</td> <td class="divider_bottom" rowspan="3">Daily, days 1 though 5</td> </tr> <tr> <td style="border-bottom-color: white;"><strong>OR</strong></td> <td style="border-bottom-color: white;"> </td> </tr> <tr class="divider_bottom"> <td>1.5 mg/m<sup>2</sup> once per day IV*</td> <td>IV: Dilute in 100 mL NS or D5W<sup>Δ</sup> and administer over 30 minutes.</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>LOW.</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Routine prophylaxis not indicated.</li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Topotecan is an irritant; however, rare severe cases of extravasation have been reported.<sup>[2]</sup></li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of neutropenic fever is 5%<sup>◊</sup><sup>[1]</sup>). In the event of severe neutropenia (ANC &lt;500/microL), hematopoietic growth factors may be considered beginning on day 6 for subsequent cycles of IV topotecan.<sup>[2]</sup></li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>Dose adjustments for topotecan in patients with renal impairment are recommended.</li> <li>Refer to UpToDate topics on chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC with differential and platelet count weekly during treatment.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Basic metabolic panel and liver function tests prior to each cycle.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>Prior to administration of the first course of treatment, patients should have a platelet count of &gt;100,000/mm<sup>3</sup> and an ANC &gt;1000/microL.<sup>[2,3]</sup> For IV topotecan: If the ANC falls below 500/microL or platelets fall below 25,000/microL at any time during the cycle, consider dose-reducing IV topotecan by 0.25 mg/m<sup>2</sup> per day, for subsequent cycles. An alternative for patients who develop severe neutropenia is administering granulocyte-colony stimulating factors for subsequent courses (starting on day 6 of the subsequent cycle) before resorting to dose reduction.<sup>[2]</sup> IV topotecan-associated neutropenia may predispose to neutropenic colitis. In patients presenting with fever, neutropenia, and a compatible picture of abdominal pain with or without diarrhea, neutropenic colitis should be suspected.</li> <li>Refer to UpToDate topics on neutropenic enterocolitis (typhlitis).</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Pulmonary toxicity</strong></td> <td colspan="3"> <ul> <li>IV topotecan has been associated with fatal reports of interstitial lung disease. Monitor patients for pulmonary symptoms indicative of interstitial lung disease and discontinue topotecan if a new diagnosis of interstitial lung disease is confirmed.<sup>[2,3]</sup></li> <li>Refer to UpToDate topics on pulmonary toxicity associated with antineoplastic therapy, cytotoxic agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Diarrhea</strong></td> <td colspan="3"> <ul> <li>Hold oral topotecan for grade 3 or 4 diarrhea. When resolved to ≤grade 1, reduce dose by 0.4 mg/m<sup>2</sup> per day for subsequent cycles.<sup>[3]</sup></li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">IV: intravenous; NS: normal saline; D5W: 5% dextrose in water; ANC: absolute neutrophil count; CBC: complete blood count.<br/>* Although dose escalations were permitted on the original clinical trial,<sup>[1]</sup> our practice is to avoid escalations, given toxicities associated with this agent.<br/>¶ Reduce the dose to the nearest 0.25 mg and prescribe the minimum number of 1-mg and 0.25-mg capsules.<br/>Δ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br/><font class="lozenge">◊</font> Some experts do administer hematopoietic growth factor support with topotecan, due to some data demonstrating high rates of severe neutropenia.<sup>[4]</sup></div><div class="graphic_reference">References: 

<ol>
<li>Eckardt JR, et al. J Clin Oncol 2007; 25:2086.</li>
<li>Topotecan hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">www.dailymed.nlm.nih.gov</a>, accessed on March 7, 2019).</li>
<li>Topotecan hydrochloride capsule. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">www.dailymed.nlm.nih.gov</a>, accessed on March 7, 2019).</li>
<li>von Pawel J, et al. J Clin Oncol 1999; 17:658.</li></ol></div><div id="graphicVersion">Graphic 122616 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
